MacroGenics Inc earnings missed, revenue fell short of estimates
MacroGenics Inc (MGNX) reported Q3 EPS of -$0.29, matching estimates, but revenue of $36.6M missed the $40.6M consensus. The stock is down 42.82% over 3 months but up 69.85% year-over-year. InvestingPro rates its financial health as 'fair performance'.
How this was made
The 30-second read
Why it matters
A reported EPS and revenue shortfall is a direct negative earnings catalyst that can drive near-term repricing and volatility, especially for small-cap biotech names.
Market read
Traders can use the miss versus consensus to reassess near-term expectations and risk for MGNX ahead of subsequent updates.
What to watch
The article does not include guidance, cash runway, or pipeline updates, so traders may be over-weighting the single-quarter miss without assessing forward fundamentals.
Background
The piece summarizes MacroGenics’ Q3 results versus analyst consensus and notes recent stock performance and EPS revision counts.
Ticker impact
MacroGenics reported Q3 EPS of -0.29 and revenue of $36.6M, both below consensus, signaling weaker-than-expected fundamentals.
Likely downside pressure as the market reprices expectations after the reported miss versus consensus.
The article provides the company’s own quarterly EPS and revenue versus consensus, which is a direct earnings catalyst for the stock.
Market effects
Biotech/biopharma sentiment may soften at the margin when a single-name results print disappoints, but no sector-wide signal is provided.
Limited, as the article is company-specific with no broader regional macro or peer read-across.
Low, no international supply, regulation, or cross-border catalyst is mentioned.
Counterpoint
If the miss is driven by timing of revenue recognition rather than underlying demand, the stock could stabilize once investors focus on longer-term pipeline progress (not discussed here).
Key entities
- companyMacroGenics Inc
NASDAQ-listed biotech issuer reporting Q3 EPS and revenue versus consensus.
